RxSight, Inc. (RXST)
After hours:
| Previous Close | 60.66 |
| Open | 57.72 |
| Bid | 61.24 x 100 |
| Ask | 61.48 x 200 |
| Day's Range | 57.11 - 63.28 |
| 52 Week Range | 20.66 - 66.54 |
| Volume | |
| Avg. Volume | 440,019 |
| Market Cap | 2.285B |
| Beta (5Y Monthly) | 1.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.24 |
| Earnings Date | Aug 05, 2024 - Aug 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 72.43 |
Simply Wall St.RxSight First Quarter 2024 Earnings: Beats Expectations
RxSight ( NASDAQ:RXST ) First Quarter 2024 Results Key Financial Results Revenue: US$29.5m (up 69% from 1Q 2023). Net...
GlobeNewswireRxSight, Inc. Announces Pricing of Public Offering of Common Stock
ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it has priced its underwritten public offering. RxSight expects to sell 1,785,714 shares of its common stock at a price to the public of $56.00 per share. RxSight has granted the underwriters a 30-day option to purchase up to an additional 267,857 shares of its
- GlobeNewswire
RxSight, Inc. Announces Proposed Public Offering of Common Stock
ALISO VIEJO, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., (Nasdaq: RXST), an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, announced today that it intends to offer and sell, subject to market and other conditions, $100 million of shares of its common stock in an underwritten public offering. In addition, RxSight expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the
